Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Eggshell-Derived Hydroxyapatite With Platelet-Rich Fibrin for Bone Regeneration After Jaw Cyst Removal

5. november 2026 opdateret af: Ahmed Nasser Ali Mabkhout

Evaluation of Eggshell-Derived Hydroxyapatite Enhanced With Platelet-Rich Fibrin for Alveolar Bone Regeneration Following Cyst Enucleation

This clinical study aims to evaluate bone healing after the surgical removal of jaw cysts using a bone graft material made from chicken eggshells, with or without platelet-rich fibrin (PRF), a substance prepared from the patient's own blood.

Removal of a jaw cyst can leave an empty space in the surrounding bone. Although this space may heal naturally, bone regeneration can take several months. Hydroxyapatite is a bone-like mineral that may support new bone formation. Combining it with PRF may further improve healing.

This prospective, controlled clinical study is being conducted in Sana'a, Yemen. Participants undergo surgical removal of jaw cysts and receive one of the treatment approaches included in the study. The researchers compare bone healing between treatment groups using clinical examinations and dental imaging, including cone-beam computed tomography (CBCT).

Participants are followed for up to six months after surgery. The study evaluates bone regeneration, postoperative pain, wound healing, and possible complications.

The researchers aim to determine whether eggshell-derived hydroxyapatite combined with PRF improves bone regeneration compared with the other treatments being investigated.

Studieoversigt

Detaljeret beskrivelse

This prospective, controlled, non-randomized interventional clinical study evaluates the clinical and radiographic outcomes of eggshell-derived hydroxyapatite (HA) enhanced with autologous platelet-rich fibrin (PRF) for alveolar bone regeneration following the enucleation of odontogenic jaw cysts.

The study is conducted in Sana'a, Yemen, among adult patients requiring surgical enucleation of jaw cysts associated with residual bone defects.

The investigational bone graft material is synthesized from processed chicken eggshells using a chemical preparation method involving phosphoric acid. The resulting calcium phosphate material undergoes physicochemical characterization and is prepared for clinical application under controlled aseptic conditions.

The clinical study includes three treatment groups. Participants are assigned using a repeating A-B-C allocation sequence rather than random assignment. The study evaluates eggshell-derived HA combined with autologous PRF against the other treatment approaches defined in the clinical protocol.

When PRF is used, venous blood is collected from the participant and centrifuged without anticoagulants to obtain a fibrin-rich preparation. The PRF is combined with the prepared HA material and applied to the residual bone defect after cyst enucleation.

Participants undergo standardized surgical management and postoperative clinical assessment. Clinical evaluations include wound healing, postoperative pain, swelling, infection, wound dehiscence, and other treatment-related complications.

Radiographic assessments include panoramic radiography and cone-beam computed tomography (CBCT). Bone regeneration is evaluated through changes in residual defect dimensions and radiographic healing during postoperative follow-up, including assessments at three and six months.

The primary objective is to compare radiographic bone regeneration following cyst enucleation among the treatment groups. Secondary objectives include evaluating soft tissue healing, postoperative discomfort, and treatment-related complications.

The study hypothesis is that eggshell-derived HA combined with autologous PRF may provide improved bone regeneration compared with the other treatment approaches. The investigation is intended to generate clinical evidence regarding the regenerative performance and safety of the locally prepared bone graft material.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

30

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Sanaa, Yemen
        • Rekruttering
        • Faculty of Dentistry, Sana'a University
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 60 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

**Inclusion Criteria:**

  • Adult patients aged 18 to 60 years.
  • Patients diagnosed with odontogenic jaw cysts requiring surgical enucleation.
  • Patients with residual jawbone defects measuring at least 1.5 cm following cyst enucleation.
  • Patients in good general health or with medically controlled systemic conditions.
  • Patients who provide informed consent to participate in the clinical study and agree to scheduled postoperative follow-up examinations.

**Exclusion Criteria:**

  • Patients with an active infection at the surgical site.
  • Patients with a history of radiation therapy or bisphosphonate use.
  • Patients with systemic bone diseases or immunosuppression.
  • Pregnant or lactating women.
  • Patients with known allergies or intolerance to any materials used in the study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Group A: Eggshell-Derived HA + PRF

Following surgical enucleation of the odontogenic jaw cyst, the residual bone defect is filled with locally prepared eggshell-derived hydroxyapatite combined with autologous platelet-rich fibrin (PRF). The PRF is obtained from the patient's venous blood by centrifugation without anticoagulants. The combined graft is placed into the bone cavity before surgical wound closure.

Aktiv komparator: Group B: Eggshell-Derived HA Alone

Following surgical enucleation of the odontogenic jaw cyst, the residual bone defect is filled with eggshell-derived hydroxyapatite without platelet-rich fibrin. The graft is placed directly into the bone cavity before surgical wound closure.

Ingen indgriben: Group C: Spontaneous Bone Healing

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Alveolar Bone Defect Dimensions Following Cyst Enucleation
Tidsramme: Baseline and 3 and 6 months after surgery

Radiographic bone regeneration is assessed by measuring changes in the vertical and horizontal dimensions of the residual bone defect in millimeters using cone-beam computed tomography (CBCT). Measurements obtained at baseline are compared with those at 3 and 6 months after surgery to evaluate bone defect reduction among the treatment groups.

Baseline and 3 and 6 months after surgery
Change in Radiographic Density Within the Healing Bone Defect
Tidsramme: Baseline and 3 and 6 months after surgery

Changes in radiographic density within the bone defect are evaluated using CBCT image gray values obtained from a defined region of interest. Measurements are compared between baseline and follow-up examinations at 3 and 6 months, using a consistent imaging and measurement protocol. Gray values are reported as relative radiographic measurements rather than calibrated Hounsfield units.

Baseline and 3 and 6 months after surgery

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Postoperative Pain Intensity
Tidsramme: 1 week, 1 month, 3 months, and 6 months after surgery

Postoperative pain is assessed using a patient-reported visual analog scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain). Pain scores are recorded during postoperative follow-up visits and compared among the treatment groups.

1 week, 1 month, 3 months, and 6 months after surgery
Clinical Soft Tissue Healing
Tidsramme: 1 week, 1 month, 3 months, and 6 months after surgery

Healing of the surgical site is assessed clinically by examining mucosal wound closure and recording the presence or absence of swelling and wound dehiscence during postoperative follow-up visits.

1 week, 1 month, 3 months, and 6 months after surgery
Incidence of Postoperative Complications
Tidsramme: From surgery through 6 months of postoperative follow-up

The number of participants experiencing postoperative complications, including surgical-site infection, wound dehiscence, or other documented procedure-related complications, is recorded and compared among the treatment groups.

From surgery through 6 months of postoperative follow-up

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

14. september 2026

Primær færdiggørelse (Anslået)

30. december 2027

Studieafslutning (Anslået)

30. december 2027

Datoer for studieregistrering

Først indsendt

5. november 2026

Først indsendt, der opfyldte QC-kriterier

5. november 2026

Først opslået (Faktiske)

12. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Individual participant data (IPD) will not be shared with external researchers. Participant-level clinical and radiographic data will be kept confidential in accordance with the approved study protocol, institutional ethical requirements, and applicable data protection regulations. Aggregated and anonymized study results may be reported in scientific publications.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner